A randomized trial of cefepime and ceftazidime for the treatment of community-acquired pneumonia

Journal of Chemotherapy

Volumn 11, Issue 4, 1999, Pages 273-277

  Bonfitto, Piergiuseppe ^a,f   Lamorgese, V ^a   De Vietro, T ^g   Malerba, M ^b   Rizzello, L ^c   Scoditti, S ^d   Zuin, R ^e  

^a S Michele M Laureto Hospital   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d First Division of Pneumology   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f Divisions di Pneumologia   (Italy)

^g NONE

Author keywords

Cefepime; Ceftazidime; Community acquired pneumonia (CAP); Lower respiratory tract infection; Pneumonia; Randomized trial

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMORBIDITY; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

EID: 0032791881     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.4.273     Document Type: Article

References (18)

1. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618-1624.
2. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobical therapy. Am Rev Respir Dis 1993; 148: 1418-1426.
3. Berntsson E, Blomberg J, Lagergard T, Trollfors B. Etiology of community-acquired pneumonia in patients requiring hospitalization. Eur J Clin Microbiol 1985; 4: 268-272.
4. Lieberman D, Schloeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one-year prospective study of 346 consecutive patients. Thorax 1996; 51: 179-184.
5. Neill AM, Martin JR, Weir R, et al. Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010-1016.
6. Niederman MS, Fein AM. Pneumonia in elderly. Clin Geriatr Med 1986; 2: 241-268.
7. Moine P, Vercken JB, Chevret S, Chastang C. Severe community-acquired pneumonia. Chest 1994; 105: 1487-1495.
8. Ewing S, Bauer T, Hasper E, et al. Value of routine microbial investigation in community-acquired pneumonia treated in a tertiary care center. Respiration 1996; 63: 164-169.
9. Bohte R, van Furth R, van den Brock PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995; 50: 543-547.
10. Porath A, Schlaefler F, Lieberman D. The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect 1997; 34: 41-48.
11. Leophonte P, Bertrand A, Nouvet G, et al. A comparative study of cefepime vs ceftzidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother 1993; 32: 165-173.
12. Kieft H, Hoepelman AI, Rozenberg-Arska M, et al. Cefepime compared with ceftazidirne as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrob Agents Chemother 1994; 38: 415-421.
13. Schrank JH, Kelly JW, McAllister CK. Randomized comparison of cefepime and ceftazidirne for treatment of hospitalized patients with gram-negative bacteremia. Clin Infect Dis 1995; 20: 56-58.
14. Kalman D, Barriere SL, Johnson BL. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime and cefoperazone in serum and blister fluid. Antimicrob Agents Chemother 1992; 36: 453-457.
15. Barradel LB, Bryson HM. Cefepime, a review of its antibacterial activity, pharmacokinetics properties and therapeutic use. Drugs 1994; 47: 471-505.
16. Hoepelman AIM, Kieft H, Aoun M, et al. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. J Antimicrob Chemother 1993; 32: 175-186.
17. Edelstein H, Chirurgi V, Oster S, et al. A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia. J Antimicrob Chemother 1991; 28: 569-575.
18. Clarke MJ, Paladino JA. Pharmacoeconomic comparison cefepime vs ceftazidime in septic patients. J Infect Dis Pharm 1996; 2: 1-14.